Peridontal DiseaseNCT06635369
Taurine in Periodontitis and Aging
A study testing Periodontal Indices in people with Peridontal Disease and Aging, run by Istanbul Medipol University Hospital at 1 site in Turkey (Türkiye).
Trial summary
Aging leads to a decline in physiological functions and increases the risk of chronic diseases. Periodontitis is a chronic inflammatory disease that causes progressive destruction of the tissues supporting the teeth. Read more about this study
- Who is it for?
- Ages 26 years and olderHealthy volunteers can take part
- Conditions the study is for
- Peridontal Disease, Aging
- What is being tested?
- Periodontal Indices
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 66 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 21 Dec 2023to 1 Jun 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 26 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- ages 18-25 or 45-64
- use of antibiotics, anti-inflammatory drugs, immunosuppressants, beta-blockers, calcium channel blockers, or anticoagulants within the last 6 months
- presence of diabetes, rheumatoid arthritis, or other systemic conditions such as cardiovascular, renal, hepatic, and neurodegenerative disorders
- pregnancy or lactation
- alcoholism
- smoking
Show all 9Show fewer
- nonsurgical periodontal treatment in the past 6 months or surgical treatment in the past 12 months
- having less than 20 natural teeth, excluding third molars
- use of orthodontic appliances
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Istanbul Medipol University
Istanbul, Unkapani
About this study
Official title: The Role of Taurine in Periodontitis and Aging: a Preliminary Study
Aging leads to a decline in physiological functions and increases the risk of chronic diseases. Periodontitis is a chronic inflammatory disease that causes progressive destruction of the tissues supporting the teeth. Taurine, an amino acid with anti-inflammatory and antioxidant effects, might impact both periodontitis and aging. This study investigated taurine, SIRT1, and TNF-α levels in saliva and blood of 66 healthy people in different age groups, with or without periodontal disease. The findings showed that young people with healthy periodontal status had higher levels of taurine and SIRT1 compared to others. TNF-α, a marker of inflammation, was linked to the severity of periodontitis and may help identifying it in younger individuals. Overall, higher TNF-α levels are associated with periodontal inflammation, while taurine levels decrease with age-related inflammation.
- Conditions
- Peridontal Disease, Aging
- Being tested
- Periodontal Indices
- Keywords
- Taurine, Periodontitis, Aging, Inflammation, TNF-α, SIRT1, Biomarker
- Medical subject headings
- Periodontitis, Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Periodontal IndicesDiagnostic test
Also called Salivary Flow Rate, TNF-α Levels, SIRT1 Levels, Taurine Levels
Saliva, serum and periodontal indexes were obtained from patients
| Study group | Role | What they receive |
|---|---|---|
| Young (25-44 years) with a healthy periodontium | Experimental | Not described Receives: Diagnostic Test: Periodontal Indices |
| young (25-44 years) with Periodontitis | Experimental | Not described Receives: Diagnostic Test: Periodontal Indices |
| Old (≥65 years) with a healthy periodontium | Experimental | Not described Receives: Diagnostic Test: Periodontal Indices |
| Old (≥65 years) with Periodontitis | Experimental | Not described Receives: Diagnostic Test: Periodontal Indices |
What is being measured
The primary outcome is the main question the study is designed to answer.
Taurine
Taurine levels in saliva and serum were measured
Measured: 12 Weeks
SIRT1
SIRT1 levels in saliva and serum were measured
Measured: 12 Weeks
TNF-α
TNF-α levels in saliva and serum were measured
Measured: 12 Weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Oct 2024
- Study start21 Dec 2023
- Primary completion1 May 2024
- Study completion1 Jun 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Peridontal DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Participants are separated into four different groups. Young (25-44 years) with a healthy periodontium, young with periodontitis, old (≥65 years) with a healthy periodontium, and old with periodontitis
- Masking
- None (open label)
- Enrolment
- 66 participants (actual)
Sponsor and investigators
- Lead sponsor
- Istanbul Medipol University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hadi Sayedyousef, Istanbul Medipol University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06635369
- Sponsor's protocol ID
- 1078
- Status last verified
- Oct 2024
- First submitted
- 4 Oct 2024
- Last updated
- 10 Oct 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Due to patients data privacy
Publications
Sayedyousef H, Yilmaz O, Ozturk C, Demir B, Toygar HU, Balci N. Taurine, Sirtuin-1 and TNF- alpha levels in different aged adults with periodontitis: a pilot study. BMC Oral Health. 2025 Aug 22;25(1):1354. doi: 10.1186/s12903-025-06690-z.
PubMed 40847336
Study at a glance
From the registry record, last updated by the sponsor on 10 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of Taurine in Periodontitis and Aging: a Preliminary Study
- ClinicalTrials.gov ID
- NCT06635369
- Acronym / sponsor ID
- 1078
- Conditions
- Peridontal Disease, Aging
- Keywords
- Taurine, Periodontitis, Aging, Inflammation, TNF-α, SIRT1, Biomarker
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 66 participants (actual)
- Lead sponsor
- Istanbul Medipol University HospitalUniversity, hospital or other
- Study start
- 21 Dec 2023 (actual)
- Primary completion
- 1 May 2024 (actual)
- Study completion
- 1 Jun 2024 (actual)
- First posted
- 10 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aging leads to a decline in physiological functions and increases the risk of chronic diseases. Periodontitis is a chronic inflammatory disease that causes progressive destruction of the tissues supporting the teeth. Taurine, an amino acid with anti-inflammatory and antioxidant effects, might impact both periodontitis and aging. This study investigated taurine, SIRT1, and TNF-α levels in saliva and blood of 66 healthy people in different age groups, with or without periodontal disease. The findings showed that young people with healthy periodontal status had higher levels of taurine and SIRT1 compared to others. TNF-α, a marker of inflammation, was linked to the severity of periodontitis and may help identifying it in younger individuals. Overall, higher TNF-α levels are associated with periodontal inflammation, while taurine levels decrease with age-related inflammation.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
- Model description
- Participants are separated into four different groups. Young (25-44 years) with a healthy periodontium, young with periodontitis, old (≥65 years) with a healthy periodontium, and old with periodontitis
| Arm | Type | Receives |
|---|---|---|
| Young (25-44 years) with a healthy periodontium | Experimental | Diagnostic Test: Periodontal Indices |
| young (25-44 years) with Periodontitis | Experimental | Diagnostic Test: Periodontal Indices |
| Old (≥65 years) with a healthy periodontium | Experimental | Diagnostic Test: Periodontal Indices |
| Old (≥65 years) with Periodontitis | Experimental | Diagnostic Test: Periodontal Indices |
Who may qualify
- Ages
- 26 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (9 listed)
- ages 18-25 or 45-64
- use of antibiotics, anti-inflammatory drugs, immunosuppressants, beta-blockers, calcium channel blockers, or anticoagulants within the last 6 months
- presence of diabetes, rheumatoid arthritis, or other systemic conditions such as cardiovascular, renal, hepatic, and neurodegenerative disorders
- pregnancy or lactation
- alcoholism
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Periodontal IndicesAlso: Salivary Flow Rate, TNF-α Levels, SIRT1 Levels, Taurine LevelsSaliva, serum and periodontal indexes were obtained from patients | Diagnostic test | Old (≥65 years) with Periodontitis, Old (≥65 years) with a healthy periodontium, Young (25-44 years) with a healthy periodontium, young (25-44 years) with Periodontitis |
Primary outcome
Taurine
Time frame: 12 Weeks
Taurine levels in saliva and serum were measured
SIRT1
Time frame: 12 Weeks
SIRT1 levels in saliva and serum were measured
TNF-α
Time frame: 12 Weeks
TNF-α levels in saliva and serum were measured
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Oct 2024.
- Derived from this study: PubMed 40847336Sayedyousef H, Yilmaz O, Ozturk C, Demir B, Toygar HU, Balci N. Taurine, Sirtuin-1 and TNF- alpha levels in different aged adults with periodontitis: a pilot study. BMC Oral Health. 2025 Aug 22;25(1):1354. doi: 10.1186/s12903-025-06690-z.
- Individual participant dataSharing planned: No. Due to patients data privacy
Related trials for Peridontal Disease
Not yet recruitingObservational study
Assessment of Peridontal Inflamatuar Markers in MIH
Molar-Incisor Hypomineralization (MIH)
RecruitingObservational study
Peridontal and Intestinal Microbiota in Patients With Gingival Scarring Pemphigoid
Pemphigoid, Benign Mucous Membrane, Gingivitis Hyperplastic
RecruitingPhase 3
Efficacy of Resveratrol Containing Mouthwash in Reducing Halitosis Related Porphyrymonas Gingivalis.
Halitosis, Mouth Disease
Recruiting
The Effect of Hypnosis on Periodontal Treatment
Peridontal Disease, Dental Anxiety
Recruiting
Assessment of Pro-Resolution Mediator Levels in Periodontitis Stage III and IV Before and After Periodontal Therapy
Peridontal Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Periodontal Indices in people with Peridontal Disease and Aging, run by Istanbul Medipol University Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Taurine (time frame: 12 Weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06635369, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Oct 2024.